Purpose: To conduct a systematic review of reasons for and sociodemographic and disease characteristics associated with complementary and alternative medicine (CAM) use in cancer patients. Methods: Eligible studies were identified by searching the following databases: Alt Health Watch, AMED, CINAHL, CancerLit, PremMEDLINE, MEDLINE, Pub-Med, Ingenta, EMBASE, and Health Star, as well as reference lists in review articles. Only English-language articles published between 1994 and 2004 were included. Search terms included CAM and oncology/cancer, decision making and CAM and oncology/cancer, treatment decision making and CAM and oncology/cancer, and health care choices and CAM and oncology/cancer. Results: Fifty-two eligible studies were identified and summarized. These studies were conducted in 14 different countries, with the largest number of studies being completed in the United States (34.6%) . A therapeutic response, wanting control, a strong belief in CAM, CAM as a last resort, and finding hope were the most commonly cited reasons for using CAM. Age, socioeconomic status, and gender were the dominant characteristics associated with CAM use. Conclusion: Reasons for and characteristics associated with CAM use among cancer patients have been studied extensively. Future CAM research among cancer patients should focus on identifying decision-making processes and building theoretical decision-making models. These can be used in the development of decisional aids for patients when confronted with the choice to use CAM as part of their cancer treatment.
Complementary and alternative medicine (CAM) is increasingly being used by cancer patients. While definitions of CAM vary greatly, the National Center for Complementar y and Alternative Medicine (NCCAM), 1 funded by the National Institutes of Health, classifies CAM as (1) alternative medical systems, such as traditional Chinese medicine (including acupuncture), naturo-pathic medicine, ayurvedic medicine and homeopathy; (2) biologically based therapies, including herbal, special dietary and individual biological treatments not accepted by the Food and Drug Administration; (3) energy therapies such as reiki, therapeutic touch, magnet therapy, qi gong, and intercessory prayer; (4) manipulative and body based systems, for example, chiropractic, osteopathy and massage; and (5) mind-body interventions such as meditation, biofeedback, hypnotherapy and the relaxation response.
Prevalence rates of CAM use among cancer patients vary from 5% to 60%, with an average prevalence of 31.4% in adult patients. 2, 3 Initially, our intent was to review the decision-making processes used by cancer patients when confronted with the decision to use CAM as part of their treatment and to assess whether a common theoretical perspective underlies these studies. However, it became clear that there is limited literature on how this decision making occurs, as only a few authors [4] [5] [6] [7] [8] have addressed this issue. In contrast, reasons for CAM use and sociodemographic and disease characteristics associated with CAM use continue to be discussed in the literature. Therefore, a comprehensive systematic review of reasons cancer patients use CAM appeared to be a prudent first step.
Three systematic reviews 3,9,10 on CAM use among cancer patients have been published. None of these reviews included an assessment of reasons for CAM use or of characteristics of users associated with the decision to seek CAM. Therefore, the purpose of our review was to summarize and review the reasons for CAM use as well as the sociodemographic and disease characteristics associated with CAM use among cancer patients. This review will be a basis for outlining how to proceed with the development of a CAM decisionmaking theory.
Methods
Eligible studies were identified by searching the following databases from 1994 through August 2004: Alt Health Watch, AMED, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cancer Lit, Pre-MEDLINE, MEDLINE, PubMed, Ingenta, EM-BASE, and Health Star. Only English-language articles were used. Search terms included CAM and oncology/ cancer, decision making and CAM and oncology/cancer, healthcare choices and oncology/cancer and CAM, and treatment decision making and CAM and oncology/cancer. Reference lists in review articles were also searched. All articles were read in full to assess reasons for CAM use as well as patient and disease characteristics significantly associated (P < .05) with CAM use among adult cancer patients. All types of cancers were included. Abstracted items included authors, recruitment setting and sample size, study design, types of cancer, reasons for CAM use, and characteristics associated with CAM use. Qualitative studies were excluded as they did not address these issues in a standardized and objective manner. Also excluded were articles in which mere prevalence of CAM use was discussed or in which authors only described oncology patients' feelings or beliefs toward CAM. Last, we excluded articles in which a cancer diagnosis was considered a predictor for CAM use. All the articles were reviewed by 2 of the authors (M.J.V. and L.G.B.) to assess whether inclusion criteria were met.
Results
Approximately 500 articles were found, of which 52 met the inclusion criteria (Table 1) . Most studies were conducted in the United States (40.4%), Canada (17.3%), and Western Europe (21.3%), with the remainder in Asia (5.8%), the Middle East (9.6%), and Australia/New Zealand (3.8%). A wide range of CAM therapies was used, including diet and nutrition, mind-body interventions, traditional and folk remedies, pharmacological and biological treatments, manual healing methods, and herbal medicine. While many studies examined CAM use in cancer patients with all types of malignancies, studies focusing on breast or prostate cancer patients were predominant. Survey designs were most common, with data being collected by self-administered questionnaire or faceto-face interviews. Most of the studies were conducted at large urban centers.
While reasons for CAM use varied widely, a perceived beneficial response was stated most often (38.4%), followed by wanting control (17.3%), a strong belief in CAM (17.3%), CAM as a last resort (9.6%), and finding hope (9.6%). Disappointment with conventional treatment or disappointment with a conventional practitioner were mentioned in only 2 studies (3.8%). Type of cancer and study design (including sample size and geographic region) did not appear to be related to reasons for CAM use.
Sociodemographic characteristics identified most commonly across studies as being significantly associated with CAM use were age, gender, and socioeconomic status (SES). Women and younger individuals were found to be more likely to use CAM than were men and older individuals. This may be attributed to the fact that women tend to be higher users of health care and are more afflicted with chronic illnesses than are men. 11 Also, younger patients, compared to older patients, may be more likely to perceive their cancer diagnosis as a threat to their future plans. 12 Higher income and more education (indications for higher SES) appeared to be predictive of CAM use. This finding is to be expected as CAM use can be expensive, especially since it is often an out-of-pocket expense. Patients with more education may also harbor more cynicism toward the conventional system and be more aware of CAM treatments. 13, 14 A relationship between ethnicity and CAM use was not found; however, as Mackenzie et al 15 pointed out, in many surveys, ethnic minorities are underrepresented, which may lead to failure to detect relationships.
A potential interaction between geographical region and SES was apparent. In most regions of North America and Western Europe, a higher SES was associated with CAM use, whereas in Turkey and the state of Hawaii, a lower SES was associated with CAM use. 16, 17 The latter may be due to cultural factors and represent a more traditional lifestyle. 17, 18 Type of cancer appeared to interact with sociodemographic factors. In 84.6% of studies of breast cancer patients, higher education was significantly associated with CAM use. This is different from studies that included all types of cancer, in which only 23.3% of studies identified education as a characteristic associated with CAM use. Support group attendance was a more predictive factor among prostate cancer patients than among breast cancer patients. In 30% of prostate cancer studies, 5, [19] [20] [21] support group attendance was associated with CAM use, whereas only 15.4% of breast cancer studies showed a similar association. Some authors 5 suggest 
Discussion
Reasons for CAM use and characteristics associated with CAM use in cancer populations have been well documented in a wide array of cancers and populations. A major problem, however, is the wide range of CAM definitions used in the studies. The need for a standardized protocol to study CAM was highlighted in a systematic review published in 1998. 3 However, investigators have continued to use different definitions and conceptualizations. For example, some studies 14 included diet and nutritional lifestyle changes as CAM whereas others 38 used a narrower definition and included only complementary therapies such as herbs. Clearly, if the NCCAM categories were used across studies, comparison between studies would be more valid.
Most studies focused on clinic-based cancer populations. Such a sampling strategy influences the results of this review, for example, patients who forsake conventional treatment and seek alternative medicine will generally not be part of a clinic-based sample. In addition, it is possible that being asked about CAM use in a clinical setting in which attitudes toward CAM may be unfavorable 23 may have caused bias. Also, even though clinic-based samples often have a higher response rate than population-based studies, the generalizability of such studies is limited as they are case studies rather than population-based studies.
The method of statistical analysis may also influence the reported characteristics associated with CAM use. About half of the studies (25/52) used multiple regression analysis to assess whether patient and disease characteristics were related to CAM use. Studies that use only cross-tabulations and do not adjust for potential confounders are likely to overestimate such associations and thus are inaccurate.
To move our knowledge about CAM use among cancer patients forward, we must look at the process patients engage in when making the decision to use CAM as well as the context in which they make these decisions. Participants should be allowed to tell their stories rather than have their experiences forced into preconceived categories that might not capture their personal meaning, which is a potential problem when a structured questionnaire is used in data collection. It is also important to understand the meaning of CAM decision making for cancer patients including how they make sense of their own selection process. Qualitative research will be the best approach to explore and examine these complex behaviors. 24, 25 This information will allow the development of theoretical models of the decision-making process that illustrate the complexity of treatment decisions specific to CAM in the context of a cancer diagnosis. As new hypotheses regarding CAM decision making are generated through qualitative studies, meaningful quantitative studies can be designed to effectively test these hypotheses. In future studies, investigators should carefully select study methodologies that will best capture how patients make the decision to use CAM as part of their treatment regimen. The results of such studies would have important practical implications for predicting CAM use, for more effective physician-patient communication about patient intent, and for developing appropriate educational support services such as decision aids.
Decision aids have gained prominence in the past decade as a means of supporting patients in making difficult choices about treatments when the best course of action is uncertain and when conflicting benefits and risks are associated with the treatments. 26 Decision aids are typically presented during consultation with a health care professional and contain the latest, evidence-based information about possible treatments for patients. In addition, decision aids support patients in clarifying their values associated with a decision by encouraging individuals to consider the desirability or personal importance of the benefits and risks of a decision as well as their attitude toward risk when the outcome of a decision is uncertain. 27 Compared to usual care, decision aids have been found to increase patients' knowledge and active participation in treatment decisions, reduce decisional conflict and the proportion of patients who remain undecided, and assist patients in developing more realistic expectations about treatment. 27, 28 The impact of decision aids on satisfaction with decision making and health outcomes is still uncertain.
Given the conflicting scientific evidence and values associated with many CAM therapies, decision aids may prove to be an effective decisional support strategy for cancer patients contemplating CAM use in conjunction with, or as a replacement for, conventional cancer care. Receiving a cancer diagnosis is an anxiety-provoking experience, and many patients may find it difficult to make informed decisions about CAM use at this time due to the amount of stress experienced as well as the wide variety of treatment options available. In addition, patients often hold or are faced with prevalent beliefs about CAM use, such as "CAM is natural therefore it must be safe," that conflict with scientific knowledge. 29 Decision aids would promote a clear and concise process for overwhelmed cancer patients to sort through both evidence-based and lay knowledge about CAM use and integrate treatment decisions with their values and beliefs. Such decisional support may increase informed decision making about CAM and reduce the uncertainty and conflict experienced by cancer patients faced with difficult, medically complex treatment choices.
This systematic review has several limitations. The review was limited to publications in the English language; potentially relevant studies may therefore have been excluded. Pediatric populations were also excluded, limiting the generalizability of our conclusions. Many definitions of CAM are used in the literature. Keeping this in mind, we included all types of CAM in this review.
Conclusion
The characteristics of CAM users and the reasons for CAM use among adult oncology patients have been studied extensively. The widely varying and often conflicting definitions and categories of CAM make it almost impossible to draw general conclusions. In addition, given the increased integration of CAM and conventional cancer care, such studies may soon become irrelevant as the emphasis will be on packages of care, not on isolated CAM therapies. Future CAM research among oncology patients should focus on designing treatment decision-making frameworks. To do so, it is recommended that qualitative exploration precedes quantitative studies. Treatment decisionmaking frameworks can be used to develop decisional aids for oncology patients when confronted with the choice to use CAM as part of their treatment. In addition, such aids will be useful for health care providers who struggle with shared decision making in the face of a stressful, potentially life-threatening disease.
